SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Pembrolizumab Liquid Formulation

Version 4.0  Revision Date: 09/13/2019  SDS Number: 51406-00015  Date of last issue: 24.04.2019

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
   Trade name: Pembrolizumab Liquid Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
   Use of the Substance/Mixture: Pharmaceutical

1.3 Details of the supplier of the safety data sheet
   Company: MSD
   Shotton Lane
   NE23 3JU  Cramlington NU  Great Britain
   Telephone: 44 1 670 59 30 00
   Telefax: 908-735-1496
   E-mail address of person responsible for the SDS: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
   1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
   Classification (REGULATION (EC) No 1272/2008)
   Reproductive toxicity, Category 1B  H360D: May damage the unborn child.
   Specific target organ toxicity - repeated exposure, Category 2  H373: May cause damage to organs through prolonged or repeated exposure.

2.2 Label elements
   Labelling (REGULATION (EC) No 1272/2008)
   Hazard pictograms: 
   Signal word: Danger
   Hazard statements: H360D  May damage the unborn child.  H373  May cause damage to organs through prolonged or repeated exposure.
   Precautionary statements: Prevention:
   P201  Obtain special instructions before use.
**SECTION 3: Composition/information on ingredients**

### 3.2 Mixtures

<table>
<thead>
<tr>
<th>Components</th>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>EC-No.</th>
<th>Index-No.</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pembrolizumab</td>
<td>1374853-91-4</td>
<td></td>
<td></td>
<td>Repr. 1B; H360D</td>
<td>STOT RE 1; H372</td>
</tr>
</tbody>
</table>

For explanation of abbreviations see section 16.

**SECTION 4: First aid measures**

#### 4.1 Description of first aid measures

**General advice**: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

**Protection of first-aiders**: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

**If inhaled**: If inhaled, remove to fresh air. Get medical attention.

**In case of skin contact**: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact: Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed
Risks: May damage the unborn child.
May cause damage to organs through prolonged or repeated exposure.

4.3 Indication of any immediate medical attention and special treatment needed
Treatment: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media
Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

5.2 Special hazards arising from the substance or mixture
Specific hazards during firefighting: Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides
Nitrogen oxides (NOx)

5.3 Advice for firefighters
Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.
SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions:
- Use personal protective equipment.
- Follow safe handling advice and personal protective equipment recommendations.

6.2 Environmental precautions

Environmental precautions:
- Discharge into the environment must be avoided.
- Prevent further leakage or spillage if safe to do so.
- Prevent spreading over a wide area (e.g. by containment or oil barriers).
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up:
- Soak up with inert absorbent material.
- For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
- Clean up remaining materials from spill with suitable absorbent.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
- Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures:
- See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation:
- If sufficient ventilation is unavailable, use local exhaust ventilation.

Advice on safe handling:
- Do not get on skin or clothing.
- Do not breathe vapours or spray mist.
- Do not swallow.
- Avoid contact with eyes.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Keep container tightly closed.
- Take care to prevent spills, waste and minimize release to the environment.
Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage: Do not store with the following product types:

- Strong oxidizing agents
- Organic peroxides
- Explosives
- Gases

7.3 Specific end use(s)

Specific use(s): No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

**Occupational Exposure Limits**

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sucrose</td>
<td>57-50-1</td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>GB EH40</td>
</tr>
<tr>
<td></td>
<td></td>
<td>STEL</td>
<td>20 mg/m³</td>
<td>GB EH40</td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>1374853-91-4</td>
<td>TWA</td>
<td>75 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

**Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:**

<table>
<thead>
<tr>
<th>Substance name</th>
<th>End Use</th>
<th>Exposure routes</th>
<th>Potential health effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Histidine</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>83.38 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>236.45 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>20.56 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>118.2 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Ingestion</td>
<td>Long-term systemic effects</td>
<td>11.8 mg/kg bw/day</td>
</tr>
</tbody>
</table>

**Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:**

<table>
<thead>
<tr>
<th>Substance name</th>
<th>Environmental Compartment</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Histidine</td>
<td>Fresh water</td>
<td>0.1 mg/l</td>
</tr>
<tr>
<td></td>
<td>Freshwater - intermittent</td>
<td>1 mg/l</td>
</tr>
<tr>
<td></td>
<td>Marine water</td>
<td>0.01 mg/l</td>
</tr>
</tbody>
</table>
Pembrolizumab Liquid Formulation

8.2 Exposure controls

Engineering measures
Minimize workplace exposure concentrations.
If sufficient ventilation is unavailable, use with local exhaust ventilation.

Personal protective equipment

Eye protection
Wear the following personal protective equipment:
Safety glasses
Equipment should conform to BS EN 166

Hand protection

Material
Chemical-resistant gloves

Remarks
Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer.

Skin and body protection
Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential.
Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

Respiratory protection
If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type
Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance
suspension

Colour
Colorless to pale yellow

Odour
No data available

Odour Threshold
No data available

pH
5.5

Melting point/freezing point
No data available

Initial boiling point and boiling
No data available
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Pembrolizumab Liquid Formulation

range
Flash point : No data available
Evaporation rate : No data available
Flammability (solid, gas) : Not applicable
Upper explosion limit / Upper flammability limit : No data available
Lower explosion limit / Lower flammability limit : No data available
Vapour pressure : No data available
Relative vapour density : No data available
Relative density : No data available
Density : No data available
Solubility(ies)
Water solubility : No data available
Partition coefficient: n-octanol/water : No data available
Auto-ignition temperature : No data available
Decomposition temperature : No data available
Viscosity
Viscosity, dynamic : No data available
Viscosity, kinematic : No data available
Explosive properties : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.

9.2 Other information
Flammability (liquids) : No data available
Molecular weight : No data available
Particle size : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.
Pembrolizumab Liquid Formulation

10.3 Possibility of hazardous reactions
Hazardous reactions: Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid: None known.

10.5 Incompatible materials
Materials to avoid: Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects
Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
Not classified based on available information.

Skin corrosion/irritation
Not classified based on available information.

Serious eye damage/eye irritation
Not classified based on available information.

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Germ cell mutagenicity
Not classified based on available information.

Carcinogenicity
Not classified based on available information.

Reproductive toxicity
May damage the unborn child.

Components:

Pembrolizumab:
Reproductive toxicity - Assessment: May damage the unborn child. Based on data from similar materials
Pembrolizumab Liquid Formulation

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
May cause damage to organs through prolonged or repeated exposure.

Components:

Pembrolizumab:

Target Organs: Immune system
Assessment: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Pembrolizumab:

Species: Monkey
NOAEL: 200 mg/kg
Application Route: Intravenous
Exposure time: 180 d
Remarks: No significant adverse effects were reported

Species: Dog
NOAEL: 200 mg/kg
Application Route: Intravenous
Exposure time: 180 d
Remarks: No significant adverse effects were reported

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Pembrolizumab:

Inhalation: Target Organs: Immune system
Symptoms: Cough, Fatigue, Nausea, pruritis, Rash, constipation, joint pain, Diarrhoea, Pneumonia, decrease in appetite, Fever, anemia, neutropenia, musculoskeletal pain, Vomiting, confusion, Headache, Shortness of breath, Hypofunction of thyroid gland, May cause respiratory arrest, May cause, immune-mediated pneumonitis, colitis, hepatitis, nephritis
Remarks: Damage to fetus possible

SECTION 12: Ecological information

12.1 Toxicity
No data available

12.2 Persistence and degradability
No data available
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Pembrolizumab Liquid Formulation

Version 4.0  Revision Date: 09/13/2019  SDS Number: 51406-00015  Date of last issue: 24.04.2019

Date of first issue: 23.01.2015

SECTION 12: Other information

12.3 Bioaccumulative potential
   No data available

12.4 Mobility in soil
   No data available

12.5 Results of PBT and vPvB assessment
   Not relevant

12.6 Other adverse effects
   No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods
   Product: Dispose of in accordance with local regulations.
   According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.
   Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.
   Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
   If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number
   Not regulated as a dangerous good

14.2 UN proper shipping name
   Not regulated as a dangerous good

14.3 Transport hazard class(es)
   Not regulated as a dangerous good

14.4 Packing group
   Not regulated as a dangerous good

14.5 Environmental hazards
   Not regulated as a dangerous good

14.6 Special precautions for user
   Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code
   Remarks: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture
   REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).
   REACH - List of substances subject to authorisation: Not applicable

Remarks
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Pembrolizumab Liquid Formulation

Version 4.0  Revision Date: 09/13/2019  SDS Number: 51406-00015  Date of last issue: 24.04.2019
Date of first issue: 23.01.2015

(Annex XIV)
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer: Not applicable
Regulation (EC) No 850/2004 on persistent organic pollutants: Not applicable
Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals: Not applicable

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII):
Conditions of restriction for the following entries should be considered:
Number on list 3

Not applicable

Other regulations:
Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.
Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:
AICS: not determined
DSL: not determined
IECSC: not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information:
Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements
H360D: May damage the unborn child.
H372: Causes damage to organs through prolonged or repeated exposure if swallowed.

Full text of other abbreviations
Repr.: Reproductive toxicity
STOT RE: Specific target organ toxicity - repeated exposure
GB EH40: UK. EH40 WEL - Workplace Exposure Limits
GB EH40 / TWA: Long-term exposure limit (8-hour TWA reference period)
GB EH40 / STEL: Short-term exposure limit (15-minute reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AICS - Australian Inventory of Chemical Substances; ASTM - American Society
# Pembrolizumab Liquid Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.0</td>
<td>09/13/2019</td>
<td>51406-00015</td>
<td>24.04.2019</td>
<td>23.01.2015</td>
</tr>
</tbody>
</table>

Further information

Sources of key data used to compile the Safety Data Sheet:

Classification of the mixture:

<table>
<thead>
<tr>
<th>Repr. 1B</th>
<th>STOT RE 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>H360D</td>
<td>H373</td>
</tr>
</tbody>
</table>

Classification procedure:
- Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.
<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.0</td>
<td>09/13/2019</td>
<td>51406-00015</td>
<td>24.04.2019</td>
<td>23.01.2015</td>
</tr>
</tbody>
</table>